Cincinnati, Ohio – A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas (GBM), the most deadly form of brain tumors. The team, led by UC’s Pankaj Desai, PhD, and Trisha Wise-Draper, MD, PhD, has...
Latest News
Helsinki, Finland – A multidisciplinary team of scientists led by University of Helsinki report that a progressive neurodegenerative disease can be triggered by a viral infection. The mechanism relates to mitochondrial roles in antiviral defense mechanisms. The scientists report that a specific gene variant affecting the mitochondria disturb cellular antiviral...
Leeds, UK – The high-tech double-barrel nanopipette, developed by University of Leeds scientists, and applied to the global medical challenge of cancer, has – for the first time – enabled researchers to see how individual living cancer cells react to treatment and change over time – providing vital understanding that...
Bethesda, Maryland – Common inherited genetic factors that predict cancer risk in the general population may also predict elevated risk of new cancers among childhood cancer survivors, according to a study led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health. The findings, published...
AMSTERDAM, the Netherlands – GPs may soon be able to identify patients with an increased risk of lung cancer up to 4 months earlier than is currently the case. The GP should be able to simply identify patients during a consultation with an algorithm created by researchers at Amsterdam UMC...
Toronto, Canada – An important new study led by the Centre for Addiction and Mental Health (CAMH), and with partnership across several Toronto Dementia Research Alliance (TDRA) sites— Baycrest, Sunnybrook Health Science Centre, Unity Health Toronto, and University Health Network— has demonstrated that a combination therapy can slow cognitive decline in...
A new policy framework is the only way to ensure that progress made for the 30 million people living with a rare disease in Europe is not left to luck or chance during the next decade. The eight Rare 2030 recommendations, the result of the two-year participative Foresight Study led by EURORDIS-Rare...
A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children’s Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine. In the...
Auckland, New Zealand – A molecule created at the University of Auckland is one step closer to becoming a treatment for an extremely rare and severely debilitating neurological disorder called Phelan-McDermid syndrome. According to Neuren Pharmaceuticals, a biopharmaceutical company that is listed on the Australian Securities Exchange, children with the...
Nagoya, Japan – Researchers at Nagoya University in Japan and their collaborators have used a biomarker based on microbubbles to evaluate the success of near-infrared photoimmunotherapy (NIR-PIT) treatment. Using ultrasound to track the microbubbles, they were able to identify areas where cancer therapy had not been fully applied. Their findings...